WallStSmart

Aurora Cannabis Inc (ACB)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 21353% more annual revenue ($67.38B vs $314.07M). MRK leads profitability with a 3.6% profit margin vs -38.3%. MRK earns a higher WallStSmart Score of 44/100 (D).

ACB

Avoid

29

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -10.67

MRK

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACB.

MRKSignificantly Overvalued (-76.6%)

Margin of Safety

-76.6%

Fair Value

$84.66

Current Price

$146.72

$62.06 premium

UndervaluedFair: $84.66Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACB2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$368.89B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

ACB4 concerns · Avg: 2.5/10
Market CapQuality
$257.04M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-7.9%2/10

ROE of -7.9% — below average capital efficiency

Revenue GrowthGrowth
-8.8%2/10

Revenue declined 8.8%

MRK4 concerns · Avg: 3.5/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ACB

The strongest argument for ACB centers on Price/Book, Debt/Equity.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ACB

The primary concerns for ACB are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

ACB profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

ACB carries more volatility with a beta of 1.42 — expect wider price swings.

MRK is growing revenue faster at 4.7% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (44/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aurora Cannabis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?